,?

Leonardo Quarta1, Francesco Pellegrino1, Armando Stabile1

  • 1Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

European urology focus
|December 24, 2025
PubMed
概括

前列腺特异性抗原密度 (PSAD) 临床显著前列腺癌 (csPCa) 的风险因前列腺大小而异. 在PI-RADS 3病变和更大的前列腺 (>40毫升) 的男性中,PSAD对于cSPCa检测更有价值.